Literature DB >> 31885322

The double dealing of cyclin D1.

Guergana Tchakarska1, Brigitte Sola2.   

Abstract

The cell cycle is tightly regulated by cyclins and their catalytic moieties, the cyclin-dependent kinases (CDKs). Cyclin D1, in association with CDK4/6, acts as a mitogenic sensor and integrates extracellular mitogenic signals and cell cycle progression. When deregulated (overexpressed, accumulated, inappropriately located), cyclin D1 becomes an oncogene and is recognized as a driver of solid tumors and hemopathies. Recent studies on the oncogenic roles of cyclin D1 reported non-canonical functions dependent on the partners of cyclin D1 and its location within tumor cells or tissues. Support for these new functions was provided by various mouse models of oncogenesis. Finally, proteomic and transcriptomic data identified complex cyclin D1 networks. This review focuses on these aspects of cyclin D1 pathophysiology, which may be crucial for targeted therapy.Abbreviations: aa, amino acid; AR, androgen receptor; ATM, ataxia telangectasia mutant; ATR, ATM and Rad3-related; CDK, cyclin-dependent kinase; ChREBP, carbohydrate response element binding protein; CIP, CDK-interacting protein; CHK1/2, checkpoint kinase 1/2; CKI, CDK inhibitor; DDR, DNA damage response; DMP1, cyclin D-binding myb-like protein; DSB, double-strand DNA break; DNA-PK, DNA-dependent protein kinase; ER, estrogen receptor; FASN, fatty acid synthase; GSK3β, glycogen synthase-3β; HAT, histone acetyltransferase; HDAC, histone deacetylase; HK2, hexokinase 2; HNF4α, and hepatocyte nuclear factor 4α; HR, homologous recombination; IR, ionizing radiation; KIP, kinase inhibitory protein; MCL, mantle cell lymphoma; NHEJ, non-homologous end-joining; PCAF, p300/CREB binding-associated protein; PGC1α, PPARγ co-activator 1α; PEST, proline-glutamic acid-serine-threonine, PK, pyruvate kinase; PPAR, peroxisome proliferator-activated receptor; RB1, retinoblastoma protein; ROS, reactive oxygen species; SRC, steroid receptor coactivator; STAT, signal transducer and activator of transcription; TGFβ, transforming growth factor β; UPS, ubiquitin-proteasome system; USP22, ubiquitin-specific peptidase 22; XPO1 (or CRM1) exportin 1.

Entities:  

Keywords:  Cancer; DNA repair; cyclin; migration; proliferation; transcription

Mesh:

Substances:

Year:  2019        PMID: 31885322      PMCID: PMC6961668          DOI: 10.1080/15384101.2019.1706903

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  117 in total

Review 1.  New roles of cyclin D1.

Authors:  Richard G Pestell
Journal:  Am J Pathol       Date:  2013-07       Impact factor: 4.307

2.  Requirement for CDK4 kinase function in breast cancer.

Authors:  Qunyan Yu; Ewa Sicinska; Yan Geng; Marie Ahnström; Agnieszka Zagozdzon; Yinxin Kong; Humphrey Gardner; Hiroaki Kiyokawa; Lyndsay N Harris; Olle Stål; Piotr Sicinski
Journal:  Cancer Cell       Date:  2006-01       Impact factor: 31.743

3.  Cyclin D1 interacts and collaborates with Ral GTPases enhancing cell detachment and motility.

Authors:  R M H Fernández; M Ruiz-Miró; X Dolcet; M Aldea; E Garí
Journal:  Oncogene       Date:  2011-01-17       Impact factor: 9.867

4.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 5.  Cell cycle, CDKs and cancer: a changing paradigm.

Authors:  Marcos Malumbres; Mariano Barbacid
Journal:  Nat Rev Cancer       Date:  2009-03       Impact factor: 60.716

6.  Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity.

Authors:  Chenguang Wang; Saijun Fan; Zhiping Li; Maofu Fu; Mahadev Rao; Yongxian Ma; Michael P Lisanti; Chris Albanese; Benita S Katzenellenbogen; Peter J Kushner; Barbara Weber; Eliot M Rosen; Richard G Pestell
Journal:  Cancer Res       Date:  2005-08-01       Impact factor: 12.701

7.  The requirement for cyclin D function in tumor maintenance.

Authors:  Yoon Jong Choi; Xiaoyu Li; Per Hydbring; Takaomi Sanda; Joanna Stefano; Amanda L Christie; Sabina Signoretti; A Thomas Look; Andrew L Kung; Harald von Boehmer; Piotr Sicinski
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

8.  Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer.

Authors:  Olena Barbash; Petia Zamfirova; Douglas I Lin; Xiangmei Chen; Ke Yang; Hiroshi Nakagawa; Fengmin Lu; Anil K Rustgi; J Alan Diehl
Journal:  Cancer Cell       Date:  2008-07-08       Impact factor: 31.743

9.  Alternate cyclin D1 mRNA splicing modulates p27KIP1 binding and cell migration.

Authors:  Zhiping Li; Chenguang Wang; Xuanmao Jiao; Sanjay Katiyar; Mathew C Casimiro; George C Prendergast; Michael J Powell; Richard G Pestell
Journal:  J Biol Chem       Date:  2008-01-07       Impact factor: 5.157

10.  Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin.

Authors:  Noel P Fusté; Rita Fernández-Hernández; Tània Cemeli; Cristina Mirantes; Neus Pedraza; Marta Rafel; Jordi Torres-Rosell; Neus Colomina; Francisco Ferrezuelo; Xavier Dolcet; Eloi Garí
Journal:  Nat Commun       Date:  2016-05-16       Impact factor: 14.919

View more
  33 in total

1.  LncRNA Rian reduces cardiomyocyte pyroptosis and alleviates myocardial ischemia-reperfusion injury by regulating by the miR-17-5p/CCND1 axis.

Authors:  Hui Kang; Hui Yu; Ling Zeng; Hao Ma; Ge Cao
Journal:  Hypertens Res       Date:  2022-03-09       Impact factor: 3.872

2.  c-myc-mediated upregulation of NAT10 facilitates tumor development via cell cycle regulation in non-small cell lung cancer.

Authors:  Zimu Wang; Yicong Huang; Wanjun Lu; Jiaxin Liu; Xinying Li; Suhua Zhu; Hongbing Liu; Yong Song
Journal:  Med Oncol       Date:  2022-07-14       Impact factor: 3.738

3.  Downregulation of PLK4 expression induces apoptosis and G0/G1-phase cell cycle arrest in keloid fibroblasts.

Authors:  Ru-Lin Huang; Chuanqi Liu; Rao Fu; Yuxin Yan; Jing Yang; Xinggang Wang; Qingfeng Li
Journal:  Cell Prolif       Date:  2022-06-07       Impact factor: 8.755

4.  Silymarin inhibits the progression of Ehrlich solid tumor via targeting molecular pathways of cell death, proliferation, angiogenesis, and metastasis in female mice.

Authors:  Maggie E Amer; Maher A Amer; Azza I Othman; Doaa A Elsayed; Mohamed Amr El-Missiry; Omar A Ammar
Journal:  Mol Biol Rep       Date:  2022-03-19       Impact factor: 2.742

5.  Co-expression patterns explain how a basic transcriptional role for MYC modulates Wnt and MAPK pathways in colon and lung adenocarcinomas.

Authors:  Melanie Haas Kucherlapati
Journal:  Cell Cycle       Date:  2022-04-19       Impact factor: 5.173

6.  Unravelling of the comparative Transcriptomic Profile of Gallbladder Cancer using mRNA sequencing.

Authors:  Ruhi Dixit; Manoj Pandey; Monika Rajput; Vijay Kumar Shukla
Journal:  Mol Biol Rep       Date:  2022-04-25       Impact factor: 2.742

7.  The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions.

Authors:  Igor Odintsov; Allan J W Lui; Whitney J Sisso; Eric Gladstone; Zebing Liu; Lukas Delasos; Renate I Kurth; Exequiel M Sisso; Morana Vojnic; Inna Khodos; Marissa S Mattar; Elisa de Stanchina; Shawn M Leland; Marc Ladanyi; Romel Somwar
Journal:  Clin Cancer Res       Date:  2021-04-06       Impact factor: 12.531

8.  miR-20b-5p functions as tumor suppressor microRNA by targeting cyclinD1 in colon cancer.

Authors:  Hui Yang; Jian Lin; Jinling Jiang; Jun Ji; Chao Wang; Jun Zhang
Journal:  Cell Cycle       Date:  2020-10-12       Impact factor: 4.534

Review 9.  Targeting Reactive Oxygen Species Metabolism to Induce Myeloma Cell Death.

Authors:  Mélody Caillot; Hassan Dakik; Frédéric Mazurier; Brigitte Sola
Journal:  Cancers (Basel)       Date:  2021-05-17       Impact factor: 6.639

Review 10.  CDK4/6 Inhibitors in Melanoma: A Comprehensive Review.

Authors:  Mattia Garutti; Giada Targato; Silvia Buriolla; Lorenza Palmero; Alessandro Marco Minisini; Fabio Puglisi
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.